MedTrace Logo

RPI.4610 in Treating Patients With Metastatic Kidney Cancer

NCT00021021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-03-26

No results posted yet for this study

Summary

RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

anti-FLT-1 ribozyme

Sponsors & Collaborators

  • Ribozyome

    lead INDUSTRY

Principal Investigators

  • Robert A. Figlin, MD, FACP · Jonsson Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00021021 on ClinicalTrials.gov